Biotech RadarJobs updated

COMPANY

LB Pharmaceuticals

HQ: New York, NY source · lbpharma.us ↗ · Mid-Atlantic

Clinical Phase 3

3 open jobs · last seen Oct 23, 2026 · 9 sources

Keywords: psychiatry schizophrenia bipolar disorder Bipolar I Disorder LB-102

Profile checked Oct 10, 2026

3Open jobs$535.0MRaised (2 yrs)6Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Director, People & Culture Business PartnerNew York, United StatesNot statedOct 11, 2026
Executive Administrative AssistantSan Francisco, CaliforniaNot statedOct 11, 2026
Corporate CounselNew York, United StatesNot statedOct 11, 2026

See all 3 jobs

Timeline

  1. Raise Private placement: $150M (total, as published), announced Jul 29, 2026. Source: SEC filing. source ↗
  2. Trial start Phase 3: 52-week Open Label Safety-Tolerability Study source ↗
  3. Trial start Phase 3: Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia source ↗
  4. Raise Private placement: $100M (total, as published), announced Feb 5, 2026. Source: SEC filing. source ↗
  5. Trial start Phase 2: Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. source ↗
  6. Raise IPO: $285M (total, as published), announced Sep 11, 2025. Source: company release on GlobeNewswire. source ↗
  7. Trial start Phase 2: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia source ↗
  8. Trial start Phase 1: Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers source ↗
  9. Trial start Phase 1: Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $535.0M. Last 2 years.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT0736915452-week Open Label Safety-Tolerability StudyPhase 3RecruitingApr 23, 20262028-12 (estimated)
NCT07363577Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaPhase 3RecruitingMar 25, 20262027-06 (estimated)
NCT07494305Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.Phase 2RecruitingJan 23, 20262028-02 (estimated)
NCT06179108Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaPhase 2CompletedNov 29, 2023Dec 4, 2024 (actual)
NCT04588129Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy VolunteersPhase 1CompletedJan 5, 2021Sep 17, 2021 (actual)
NCT04187560Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy AdultsPhase 1CompletedJan 22, 2020Jul 1, 2020 (actual)

Open jobs 3

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Director, People & Culture Business PartnerNew York, United StatesNot statedOct 11, 2026Senior
Executive Administrative AssistantSan Francisco, CaliforniaNot statedOct 11, 2026Mid
Corporate CounselNew York, United StatesNot statedOct 11, 2026Mid

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at LB Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback